Philip Guilford, DO
Family Medicine · New Bern, NCNPI 1396265237
Payments from drug & device makers
Across 235 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$538
- Novo Nordisk$431
- Lilly USA, LLC$427
- AstraZeneca$325
- Boehringer Ingelheim$305
- GSK$295
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $538 |
| Novo Nordisk | 30 | $431 |
| Lilly USA, LLC | 27 | $427 |
| AstraZeneca | 18 | $325 |
| Boehringer Ingelheim | 20 | $305 |
| GSK | 17 | $295 |
| Pfizer | 10 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $146 |
| AbbVie | 8 | $122 |
| Sumitomo Pharma America, Inc. | 6 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Bayer | 5 | $106 |
| Merck | 6 | $91 |
| Daiichi Sankyo Inc. | 5 | $81 |
| Dexcom, Inc. | 5 | $76 |
| Acclarent, Inc | 1 | $73 |
| Abbott | 3 | $68 |
| Radius Health, Inc. | 3 | $52 |
| Mylan Specialty L.p. | 3 | $37 |
| Bioventus LLC | 1 | $34 |
| Exact Sciences | 2 | $28 |
| Photonicare Inc | 1 | $23 |
| Shield Therapeutics Inc | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| EKOS Corporation | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$115
How this compares
$3,850 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $131,744 |
| JardianceEmpagliflozin | 125 | $129,194 |
| EliquisApixaban | 120 | $103,401 |
| MounjaroTirzepatide | 54 | $62,117 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $30,296 |
| GemtesaVibegron | 50 | $30,181 |
| JanuviaSitagliptin Phosphate | 25 | $19,111 |
| XareltoRivaroxaban | 19 | $18,054 |
| LinzessLinaclotide | 26 | $15,359 |
| Repatha SureclickEvolocumab | 16 | $14,768 |
| MyrbetriqMirabegron | 15 | $11,707 |
| TrulicityDulaglutide | 12 | $10,913 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 48 | $10,664 |
| EntrestoSacubitril/Valsartan | 13 | $9,757 |
| FarxigaDapagliflozin Propanediol | 21 | $9,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $305 | $138,851136 claims |
| Novo NordiskOzempic | $431 | $131,744100 claims |
| PfizerEliquis | $148 | $103,401120 claims |
| Lilly USA, LLCMounjaro, Trulicity | $427 | $73,03066 claims |
| GSKTrelegy Ellipta, Shingrix | $295 | $40,96094 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $121 | $30,18150 claims |
| MerckJanuvia | $91 | $19,11125 claims |
| Johnson & JohnsonXarelto | $15 | $18,05419 claims |
| AbbVieLinzess, Synthroid | $122 | $17,21368 claims |
| AstraZenecaFarxiga | $325 | $9,75021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in New Bern
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.